Skip to main content

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Completed · Phase 3 · NCT03537508

Conditions: Healthy Volunteers (Meningococcal Infection)

At a glance

Research payments reported, 2025
$6,878
U.S. investigators named
3
Sites paid
3
Planned or actual enrollment
2,627

About the trial

Sponsor
Sanofi Pasteur, a Sanofi Company
Tested
MenACYW conjugate vaccine (biological), MenACYW-135 conjugate vaccine (biological), DTaP-IPV//Hib vaccine (biological), Pneumococcal 13-valent conjugate vaccine (biological), Pentavalent rotavirus vaccine (biological), Hepatitis B vaccine (biological), Measles, mumps, rubella (MMR) vaccine (biological), Varicella vaccine (biological), Hepatitis A vaccine (biological)
Dates
Started 2018-04-25; completion 2023-09-22
Results posted
Yes

The purpose of this study was to compare the immunogenicity and describe the safety of MenACYW conjugate vaccine and MENVEO® when both are administered concomitantly with routine pediatric vaccines to healthy infants and toddlers in the US.

From ClinicalTrials.gov, last updated 2024-10-15. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sanofi Pasteur Inc. reported $6,878 in research payments for this study in 2025 (9 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Md Trials Llc Conduct Clinical Trials $3,540
  • Primed Clinical Research Llc $1,500
  • $1,250
  • Childrens Research,llc $588

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.